Who is "They"?
Rhucin isn't even approved. Anywhere.
<<They use rhucin when someone has a breakthough attack that is on cinryse.>>>
The response rate for Cinryze in acute is over 93%. Berinert (CSL) data in acute is quite good as well. Rhucin isn't going to work 100% of the time, so you must be splitting hairs or making it up as you go along.
In the U.S. Rhucin will have to break CSL's Orphan status to get on the market at all. And even then, I'd expect Rhucin US sales to be de minimis. There would be 3 companies splitting the smaller acute market (CSL, Dyax, Pharming) and Rhucin isn't sufficiently differentiated.
In Europe not only are C1's available but also Firazyr which is a pretty good drug for acute yet only sold $6M worth in 2009. I'd expect Rhucin sales to be less than Firazyr.
News 
Market Data 
Discover 
